Qiuping Gu1, Charles F Dillon, Vicki L Burt, Richard F Gillum. 1. Division of Health and Nutrition Examination Survey, National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland, USA. qag3@cdc.gov
Abstract
BACKGROUND: Clinical trials have provided convincing evidence that blood pressure (BP) lowering treatment reduces the risk of cardiovascular disease (CVD) and total mortality. The objective of this study was to examine the association of hypertension treatment, control, and BP indexes with all-cause and cardiovascular mortality among US adults with hypertension. METHODS: Persons aged > or =18 years from the Third National Health and Nutrition Examination Survey (NHANES III) were identified as hypertensives based on a BP > or =140/90 mm Hg or current treatment for hypertension. Vital status in 2006 was ascertained by passive follow-up using the National Death Index. Cox regression models were used to assess correlates of survival. RESULTS: At baseline, 52% of hypertensive adults reported currently taking prescription medicine for high BP and 38% of treated persons had BP controlled. Compared to treated controlled hypertensives, treated uncontrolled hypertensives had a 1.57-fold (95% confidence interval (CI) 1.28-1.91) and 1.74-fold (95% CI 1.36-2.22) risk of all-cause and cardiovascular mortality; untreated hypertensives had a 1.34-fold (95% CI 1.12-1.62) and 1.37-fold (95% CI 1.04-1.81) risk of all-cause and cardiovascular mortality, respectively. The association persisted after further excluding persons with pre-existing hypertension comorbidities. Mortality risk was linearly increased with systolic BP (SBP), pulse pressure (PP), and mean arterial pressure (MBP), whereas diastolic BP (DBP) was not a significant predictor of cardiovascular mortality overall. No significant associations were observed between drug classes and mortality risk. CONCLUSIONS: This study indicates that uncontrolled and untreated hypertension was associated with increased risk of total and cardiovascular mortality among the general hypertensive population.
BACKGROUND: Clinical trials have provided convincing evidence that blood pressure (BP) lowering treatment reduces the risk of cardiovascular disease (CVD) and total mortality. The objective of this study was to examine the association of hypertension treatment, control, and BP indexes with all-cause and cardiovascular mortality among US adults with hypertension. METHODS:Persons aged > or =18 years from the Third National Health and Nutrition Examination Survey (NHANES III) were identified as hypertensives based on a BP > or =140/90 mm Hg or current treatment for hypertension. Vital status in 2006 was ascertained by passive follow-up using the National Death Index. Cox regression models were used to assess correlates of survival. RESULTS: At baseline, 52% of hypertensive adults reported currently taking prescription medicine for high BP and 38% of treated persons had BP controlled. Compared to treated controlled hypertensives, treated uncontrolled hypertensives had a 1.57-fold (95% confidence interval (CI) 1.28-1.91) and 1.74-fold (95% CI 1.36-2.22) risk of all-cause and cardiovascular mortality; untreated hypertensives had a 1.34-fold (95% CI 1.12-1.62) and 1.37-fold (95% CI 1.04-1.81) risk of all-cause and cardiovascular mortality, respectively. The association persisted after further excluding persons with pre-existing hypertension comorbidities. Mortality risk was linearly increased with systolic BP (SBP), pulse pressure (PP), and mean arterial pressure (MBP), whereas diastolic BP (DBP) was not a significant predictor of cardiovascular mortality overall. No significant associations were observed between drug classes and mortality risk. CONCLUSIONS: This study indicates that uncontrolled and untreated hypertension was associated with increased risk of total and cardiovascular mortality among the general hypertensive population.
Authors: Sheldon W Tobe; James A Stone; Todd Anderson; Simon Bacon; Alice Y Y Cheng; Stella S Daskalopoulou; Justin A Ezekowitz; Jean C Gregoire; Gord Gubitz; Rahul Jain; Karim Keshavjee; Patty Lindsay; Mary L'Abbe; David C W Lau; Lawrence A Leiter; Eileen O'Meara; Glen J Pearson; Doreen M Rabi; Diana Sherifali; Peter Selby; Jack V Tu; Sean Wharton; Kimberly M Walker; Diane Hua-Stewart; Peter P Liu Journal: CMAJ Date: 2018-10-09 Impact factor: 8.262
Authors: Carma Ayala; Jing Fang; Luis Escobedo; Stephen Pan; Hector G Balcazar; Guijing Wang; Robert Merritt Journal: Public Health Rep Date: 2012 Mar-Apr Impact factor: 2.792
Authors: Heather M Prendergast; Marina Del Rios; Renee Petzel-Gimbar; Daniel Garside; Sara Heinert; Sandra Escobar-Schulz; Pavitra Kotini-Shah; Michael Brown; Jinsong Chen; Joseph Colla; Marian Fitzgibbon; Ramon A Durazo-Arvizu; Martha Daviglus Journal: Contemp Clin Trials Date: 2017-11-08 Impact factor: 2.226
Authors: Eun Ji Kim; Taekyu Kim; Michael K Paasche-Orlow; Adam J Rose; Amresh D Hanchate Journal: J Gen Intern Med Date: 2017-02-03 Impact factor: 5.128
Authors: Y Claire Wang; Alisa M Koval; Miyabi Nakamura; Jonathan D Newman; Joseph E Schwartz; Patricia W Stone Journal: Blood Press Monit Date: 2013-02 Impact factor: 1.444
Authors: Lynn P Clemow; Thomas G Pickering; Karina W Davidson; Joseph E Schwartz; Virginia P Williams; Jonathan A Shaffer; Redford B Williams; William Gerin Journal: Transl Behav Med Date: 2018-09-08 Impact factor: 3.046